References
- 1Ministry of Health Malawi, Department of HIV/AIDS: 2021 HIV estimates for Malawi. Accessed 20/12/21
http://www.aidsmalawi.org.mw/viewresource/2021%20HIV%20EPIDEMIOLOGICAL%20ESTIMATES%20FOR%20MALAWI.pdf . - 2Ford N, Shubber Z, Meintjes G, et al. Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. The Lancet HIV. 2015; 2(10): e438–e444. DOI: 10.1016/S2352-3018(15)00137-X
- 3Matoga MM, Rosenberg NE, Stanley CC, et al. Inpatient mortality rates during an era of increased access to HIV testing and ART: A prospective observational study in Lilongwe, Malawi. PLoS ONE. 2018; 13(2):
e0191944 . DOI: 10.1371/journal.pone.0191944 - 4Gupta RK, Lucas SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS. September 24, 2015; 29(15): 1987–2002. DOI: 10.1097/QAD.0000000000000802
- 5Cox JA, Lukande RL, Lucas S, Nelson AM, Van Marck E, Colebunders R. Autopsy causes of death in HIV-positive individuals in sub-Saharan Africa and correlation with clinical diagnoses. AIDS Rev. 2010; 12(4): 183–94.
- 6World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy, July 2017. World Health Organization; 2017.
- 7Heller T, Mtemang’ombe EA, Huson MAM, et al. Ultrasound for patients in a high HIV/TB prevalence setting – A needs assessment and review of focused applications for sub-Saharan Africa. IJID. 2016; 56: 229–236. DOI: 10.1016/j.ijid.2016.11.001
- 8Ganesh P, Heller T, Chione B, et al. Near point of care HIV viral load: targeted testing at large facilities. JAIDS Journal of Acquired Immune Deficiency Syndrome. 2021; 86: 258–263. DOI: 10.1097/QAI.0000000000002555
- 9Ministry of Health and Population, Malawi. Clinical Management of HIV in children and adults. Malawi Integrated Guidelines; 2018.
- 10Lawrence DS, et al. AMBIsome Therapy Induction OptimisatioN (AMBITION): high dose ambisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a phase 3 randomised controlled non-inferiority trial. Trials. 2018; 19(1): 1–13. DOI: 10.1186/s13063-018-3026-4
- 11Cummings MJ, Goldberg E, Mwaka S, et al. The sixth vital sign: HIV status assessment and severe illness triage in Uganda. Public Health Action. 2017; 7(4): 245–250. DOI: 10.5588/pha.17.0045
- 12Burke RM, Henrion MY, Mallewa J, et al. Incidence of HIV-Related Hospital Admission and Inpatient Mortality in Malawi (2012–2019): A Population Cohort Study. Available at SSRN:
https://ssrn.com/abstract=3751320 . - 13Coetzee Lindi-Marie, et al. Cryptococcal antigen positivity combined with the percentage of HIV-seropositive samples with CD>4 counts< 100 cells/µl identifies districts in South Africa with advanced burden of disease. PloS ONE. 2018; 13(6):
e0198993 . DOI: 10.1371/journal.pone.0198993 - 14Ousley J, et al. High proportions of patients with advanced HIV are antiretroviral therapy experienced: hospitalization outcomes from 2 sub-Saharan African sites. Clinical Infectious Diseases. 2018; 66(suppl2): S126–S131. DOI: 10.1093/cid/ciy103
- 15World Health Organization (WHO) Rapid advice: Diagnosis, Prevention, and Management of Cryptococcal Disease in HIV-Infected Adults, Adolescents and Children. World Health Organization; 2011. Available from:
whqlibdoc.who.int/publications/2011/9789241502979_eng.pdf . - 16Peter JG, Zijenah LS, Chanda D, et al. Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial. The Lancet. 2016; 387(10024): 1187–1197. DOI: 10.1016/S0140-6736(15)01092-2
- 17Lawn SD, Kerkhoff AD, Burton R, et al. Diagnostic accuracy, incremental yield and prognostic value of Determine TB-LAM for routine diagnostic testing for tuberculosis in HIV-infected patients requiring acute hospital admission in South Africa: a prospective cohort. BMC Medicine. 2017; 15(1): 67. DOI: 10.1186/s12916-017-0822-8
- 18Heller T, et al. Focused assessment with sonography for HIV-associated tuberculosis (FASH): a short protocol and a pictorial review. Critical Ultrasound Journal. 2012; 4(1): 1–9. DOI: 10.1186/2036-7902-4-21
- 19Ahmed Syed AK Shifat, et al. Impact of the societal response to COVID-19 on access to healthcare for non-COVID-19 health issues in slum communities of Bangladesh, Kenya, Nigeria and Pakistan: results of pre-COVID and COVID-19 lockdown stakeholder engagements. BMJ Global Health. 2020; 5(8):
e003042 . DOI: 10.1136/bmjgh-2020-003042 - 20Hogan AB, et al. Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study. The Lancet Global Health. 2020; 8(9): e1132–e1141.
- 21Mwenge L, et al. Costs of facility-based HIV testing in Malawi, Zambia and Zimbabwe. PloS ONE. 2017; 12(10):
e0185740 . DOI: 10.1371/journal.pone.0185740 - 22Vyas S, et al. Assessing the costs and efficiency of HIV testing and treatment services in rural Malawi: implications for future “test and start” strategies. BMC Health Services research. 2020; 20(1): 1–11. DOI: 10.1186/s12913-020-05446-5
- 23Kimaro GD, Mfinanga S, Simms V, et al. The costs of providing antiretroviral therapy services to HIV-infected individuals presenting with advanced HIV disease at public health centres in Dar es Salaam, Tanzania: Findings from a randomised trial evaluating different health care strategies. PloS ONE. 2017; 12(2):
e0171917 . DOI: 10.1371/journal.pone.0171917 - 24Reddy KP, et al. Cost-effectiveness of urine-based tuberculosis screening in hospitalised patients with HIV in Africa: a microsimulation modelling study. The Lancet Global Health. 2019; 7(2): e200–e208. DOI: 10.1016/S2214-109X(18)30436-4